Professor of Pediatrics Professor of Pathology Co-Director of the MDA supported muscle disease clinic
Clinical, Teaching & Research Interests*:
Jerry R. Mendell, MD, is Director of the Center for Gene Therapy at The Research Institute at Nationwide Children’s Hospital and is a Professor of Pediatrics and Pathology at The Ohio State University (OSU) College of Medicine, and Co-Director of the MDA supported muscle disease clinic at OSU. Dr. Mendell was among the first to test muscle cell transplantation for Duchenne muscular dystrophy in the early 1990s and is the first person to study viral mediated gene therapy for muscular dystrophy in humans. Dr. Mendell has made fundamental contributions in clinical research and in the molecular genetics of neuromuscular disease. He has published major textbooks on the disorders of muscle and peripheral nerves along with more than 250 scientific articles and book chapters. In 2004, Dr. Mendell was awarded the S. Mouchly Small Scientific Achievement Award from the Muscular Dystrophy Association in recognition of his significant contributions to neuromuscular disease research.
Publications*:
King WM, Ruttencutter R, Nagaraja HN, Matkovic V, Landoll J, Hoyle C, Mendell JR, Kissel JT. Orthopedic outcomes of long-term daily corticosteroid treatment in Duchenne muscular dystrophy. Neurology 68: 1607-1613, 2007.
Tsao CY, Mendell JR. Autistic disorder in two children with mitochondrial disorder. Journal of Child Neurology 22: 1121-1123, 2007.
Rodino-Klapac LR, Janssen PM, Montgomery CL, Coley BD, Chicoine LG, Clark KR, Mendell JR. A translational approach for limb vascular delivery of the micro-dystrophin gene without high volume or high pressure for treatment of Duchenne muscular dystrophy. Journal of Translational Medicine 5: 45, 2007.
Rodino-Klapac LR, Chicoine LG, Kaspar BK, Mendell JR. Gene therapy for Duchenne muscular dystrophy: expectations and challenges. Archives of Neurology 64: 1236-41, 2007.
Mendell JR, Boué DR, Martin PT. The congenital muscular dsytrophies: Recent advances and molecular insights. In: Perspectives in Pediatric Pathology, Volume 26, Pathology of the Central Nervous System and Muscles in Fetuses, Infants and Children, (Kinney HC, Dimmick JF, Rogers BB, Singer DB, eds.) 150-170, 2007.
Mendell JR, Csimma C, McDonald CM, Escolar DM, Janis S, Porter JD, Hesterlee SE, Howell RR. Challenges in drug development for muscle disease: a stakeholders' meeting. Muscle and Nerve 35(1): 8-16, 2007.
Research Funding*:
Diverse Strategies to Correct the Dystrophin Gene Using Vascular Delivery, National Institute of Neurological Disorders and Stroke
Gentamicin Trial in Duchenne and Limb Girdle Muscular Dystrophies, National Institute of Neurological Disorders and Stroke
Implementing Newborn Screening for Duchenne Muscular Dystrophy to the Community, Centers for Disease Control and Prevention
Phase I Study of Mini-Dystrophin Gene in AAV, Anonymous/Muscular Dystrophy Association, Inc.
Early Screening and Diagnosis of Duchenne Muscular Dystrophy, Centers for Disease Control and Prevention
Clinical Thresholds and Gene Transfer in DMD and LGMD, University of Pittsburgh/National Institutes of Health
Study for Patients with Becker, Fascioscapulohumoral and Limb-Girdle Muscular Dystrophy, Anonymous
Study of Mini-Dystrophin Gene in AAV, Anonymous/Muscular Dystrophy Association Inc.
Vascular Approach to Gene Therapy for Muscular Dystrophy, Children’s National Medical Center/Department of Defense
Immunogenicity of Golden Retrievers and Normal Dogs to rAAV Vectors Carrying Mini-Dystrophin, Muscular Dystrophy Association
Transfer of Alpha-Sarcoglycan Gene to LGMD2D Patients, Muscular Dystrophy Association, Inc.
*Physician publications, awards and honors, and presentations and teaching activities represent work completed in 2007 only.
